NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|1829661130|ref|NP_001366542|]
View 

glutamyl aminopeptidase isoform 4 [Homo sapiens]

Protein Classification

M1 family metallopeptidase( domain architecture ID 10176184)

M1 family metallopeptidase containing an ERAP1-like C-terminal domain with HEAT-like repeats is a zinc-dependent metallopeptidase with an HEXXH motif as part of its active site, similar to aminopeptidase N, a broad specificity aminopeptidase, and glutamyl aminopeptidase, which releases N-terminal glutamate from a peptide

EC:  3.4.11.-
Gene Ontology:  GO:0008237|GO:0008270|GO:0006508
MEROPS:  M1

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
100-540 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


:

Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 630.38  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 100 VHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRLpELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELTP 179
Cdd:cd09601     1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSA-SLTLKGGSGIIEVTVVTDEETEFLTITLDETLPP 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 180 SSgdgLYLLTMEFAGWLNGSLVGFYRTTYT-ENGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSN 258
Cdd:cd09601    80 GE---NYTLSIEFTGKLNDDLRGFYRSSYTdEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSN 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 259 MPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFA 338
Cdd:cd09601   157 MPPVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFG 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 339 MNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWFGNIVTMDWWEDLWLNEGF 418
Cdd:cd09601   237 IPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGF 316
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 419 ASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENF 498
Cdd:cd09601   317 ATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVF 396
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|....*.
gi 1829661130 499 QKGCQMYLEKYQFKNAKTSDFWAALEEAS----RLPVKEVMDTWTR 540
Cdd:cd09601   397 RKGLRKYLKKHAYGNATTDDLWEALQEASgeskPLDVKEIMDSWTL 442
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
616-859 2.51e-63

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


:

Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 215.99  E-value: 2.51e-63
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 616 FLKINPDHIGFYRVNYEVATWDSIATALslNHKTFSSADRASLIDDAFALAR---------------------------- 667
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQL--LSKVLSPLDRAGLIDDAFALARagelstsdaldlvlaylnetdyvvwsaa 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 668 ------------------------------------------------LLRSSVLGFACKMGDREALNNASSLFEQWLNG 699
Cdd:pfam11838  79 lsqlstlrsllsadpeyealkaflrkllsplaeklgweappgeshldrQLRALLLSAACSAGDPECVAEAKKLFDAWLDG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 700 TVSLPVNLRLLVYRYGMQNsGNEISWNYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNLIKTQDVFTVI 779
Cdd:pfam11838 159 DDAIPPDLRWAVYCAAVAN-GGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDLRAVI 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 780 RYISYNSYGKNMAWNWIQLNWDYLVNRYTLNNrNLGRIVT-IAEPFNTELQLWQMESFFAKYPQAGAgEKPREQVLETVK 858
Cdd:pfam11838 238 AGLASNPAGRDLAWDFVKENWDALVKRLGGGS-SLGRLVKgLTPSFSTEEELDEVEAFFADKDTPGL-RRALAQALETIR 315

                  .
gi 1829661130 859 N 859
Cdd:pfam11838 316 R 316
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
100-540 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 630.38  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 100 VHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRLpELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELTP 179
Cdd:cd09601     1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSA-SLTLKGGSGIIEVTVVTDEETEFLTITLDETLPP 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 180 SSgdgLYLLTMEFAGWLNGSLVGFYRTTYT-ENGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSN 258
Cdd:cd09601    80 GE---NYTLSIEFTGKLNDDLRGFYRSSYTdEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSN 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 259 MPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFA 338
Cdd:cd09601   157 MPPVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFG 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 339 MNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWFGNIVTMDWWEDLWLNEGF 418
Cdd:cd09601   237 IPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGF 316
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 419 ASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENF 498
Cdd:cd09601   317 ATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVF 396
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|....*.
gi 1829661130 499 QKGCQMYLEKYQFKNAKTSDFWAALEEAS----RLPVKEVMDTWTR 540
Cdd:cd09601   397 RKGLRKYLKKHAYGNATTDDLWEALQEASgeskPLDVKEIMDSWTL 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
92-584 4.34e-127

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 395.55  E-value: 4.34e-127
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130  92 RLPDFVNPVHYDLHVKPLLEEDTYTGTVSISIN-LSAPTRYLWLHLRETRITRLpelkrpSGDQVQVRrcFEYKKQEYVV 170
Cdd:COG0308    10 YRPPGYDVTHYDLDLDLDPATTRLSGTATITFTaTEAPLDSLVLDLKGLEVTSV------TVDGKPLD--FTRDGERLTI 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 171 VEAeeelTPSSGDGLYLLTMEFAGWLNGSLVGFYRTTYTENGqvKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHP 250
Cdd:COG0308    82 TLP----KPLAPGETFTLEIEYSGKPSNGGEGLYRSGDPPDG--PPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVP 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 251 KEYGALSNMPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVF 330
Cdd:COG0308   156 AGWVAVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRML 235
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 331 DYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYREtNLLYDpKESASSNQQRVATVVAHELVHQWFGNIVTMDWWE 410
Cdd:COG0308   236 DFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGE-KVLAD-ETATDADYERRESVIAHELAHQWFGNLVTCADWD 313
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 411 DLWLNEGFASFFEFLGVNHA--ETDWQMRDQMLLEDVLPVQedDSLMSSHPIIvtVTTPDEITSVFDGISYSKGSSILRM 488
Cdd:COG0308   314 DLWLNEGFATYMEQLFSEDLygKDAADRIFVGALRSYAFAE--DAGPNAHPIR--PDDYPEIENFFDGIVYEKGALVLHM 389
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 489 LEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTWTRQMGYPVLNVNGVKNiTQKRFLLDPRANP 568
Cdd:COG0308   390 LRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAFFDQWLYQAGLPTLEVEYEYD-ADGKVTLTLRQTP 468
                         490
                  ....*....|....*.
gi 1829661130 569 SQPpsdlgYTWNIPVK 584
Cdd:COG0308   469 PRP-----HPFHIPLE 479
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
321-538 3.34e-112

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 342.35  E-value: 3.34e-112
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 321 YAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWF 400
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 401 GNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYS 480
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*....
gi 1829661130 481 KGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEAS-RLPVKEVMDTW 538
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASgPLDVDSFMDTW 219
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
202-548 3.02e-72

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 254.33  E-value: 3.02e-72
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 202 GFYRTTYTENGQVksIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSNmPVAKEESVDDKWTRTTFEKSVP 281
Cdd:TIGR02412 106 GLHRFVDPVDGEV--YLYTQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISN-SRETDVTPEPADRRWEFPETPK 182
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 282 MSTYLVCFAVHQFDSVKRISNSgKPLTIYVQPE--QKHTAEYAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAM 359
Cdd:TIGR02412 183 LSTYLTAVAAGPYHSVQDESRS-YPLGIYARRSlaQYLDADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAM 261
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 360 ENWGLITYREtNLLYDPKESASSNQQRVATVvAHELVHQWFGNIVTMDWWEDLWLNEGFASFFEFL------GVNHAETD 433
Cdd:TIGR02412 262 ENAGCVTFAE-NFLHRAEATRAEKENRAGVI-LHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLasaeatEYTDAWTT 339
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 434 W--QMRDQMLLEDVLPvqeddslmSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENFQKGCQMYLEKYQF 511
Cdd:TIGR02412 340 FaaQGKQWAYEADQLP--------TTHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAF 411
                         330       340       350
                  ....*....|....*....|....*....|....*..
gi 1829661130 512 KNAKTSDFWAALEEASRLPVKEVMDTWTRQMGYPVLN 548
Cdd:TIGR02412 412 GNATLDDLIDSLAKASGRDLSAWSDAWLETAGVNTLT 448
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
616-859 2.51e-63

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 215.99  E-value: 2.51e-63
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 616 FLKINPDHIGFYRVNYEVATWDSIATALslNHKTFSSADRASLIDDAFALAR---------------------------- 667
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQL--LSKVLSPLDRAGLIDDAFALARagelstsdaldlvlaylnetdyvvwsaa 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 668 ------------------------------------------------LLRSSVLGFACKMGDREALNNASSLFEQWLNG 699
Cdd:pfam11838  79 lsqlstlrsllsadpeyealkaflrkllsplaeklgweappgeshldrQLRALLLSAACSAGDPECVAEAKKLFDAWLDG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 700 TVSLPVNLRLLVYRYGMQNsGNEISWNYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNLIKTQDVFTVI 779
Cdd:pfam11838 159 DDAIPPDLRWAVYCAAVAN-GGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDLRAVI 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 780 RYISYNSYGKNMAWNWIQLNWDYLVNRYTLNNrNLGRIVT-IAEPFNTELQLWQMESFFAKYPQAGAgEKPREQVLETVK 858
Cdd:pfam11838 238 AGLASNPAGRDLAWDFVKENWDALVKRLGGGS-SLGRLVKgLTPSFSTEEELDEVEAFFADKDTPGL-RRALAQALETIR 315

                  .
gi 1829661130 859 N 859
Cdd:pfam11838 316 R 316
pepN PRK14015
aminopeptidase N; Provisional
303-562 2.76e-17

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 87.11  E-value: 2.76e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 303 SGK--PLTIYVQPEQKHTAEYA-ANITKSV-FDyfEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLityretNL------ 372
Cdd:PRK14015  210 SGRevALEIYVEPGNLDKCDHAmDSLKKSMkWD--EERFGLEYDLDIFMIVAVDDFNMGAMENKGL------NIfnskyv 281
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 373 LYDPkESAS-SNQQRVATVVAHELVHQWFGNIVTM-DWWEdLWLNEGFASFfeflgvnhaetdwqmRDQMLLEDVL--PV 448
Cdd:PRK14015  282 LADP-ETATdADYERIESVIAHEYFHNWTGNRVTCrDWFQ-LSLKEGLTVF---------------RDQEFSADLGsrAV 344
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 449 Q--------------EDDSLMSsHPIivtvtTPD---EI-----TSVfdgisYSKGSSILRMLEDWIKPENFQKGCQMYL 506
Cdd:PRK14015  345 KriedvrvlraaqfaEDAGPMA-HPV-----RPDsyiEInnfytATV-----YEKGAEVIRMLHTLLGEEGFRKGMDLYF 413
                         250       260       270       280       290
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 1829661130 507 EKYQFKNAKTSDFWAALEEASRLPVKEVMdTWTRQMGYPVLNVNGVKNITQKRFLL 562
Cdd:PRK14015  414 ERHDGQAVTCEDFVAAMEDASGRDLSQFR-RWYSQAGTPRVTVSDEYDAAAGTYTL 468
 
Name Accession Description Interval E-value
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
100-540 0e+00

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 630.38  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 100 VHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRLpELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELTP 179
Cdd:cd09601     1 LHYDLTLTPDLENFTFSGSVTITLEVLEPTDTIVLHAKDLTITSA-SLTLKGGSGIIEVTVVTDEETEFLTITLDETLPP 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 180 SSgdgLYLLTMEFAGWLNGSLVGFYRTTYT-ENGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSN 258
Cdd:cd09601    80 GE---NYTLSIEFTGKLNDDLRGFYRSSYTdEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALSN 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 259 MPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFA 338
Cdd:cd09601   157 MPPVESTELEDGWKTTTFETTPPMSTYLVAFVVGDFEYIESTTKSGVPVRVYARPGKIEQGDFALEVAPKILDFYEDYFG 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 339 MNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWFGNIVTMDWWEDLWLNEGF 418
Cdd:cd09601   237 IPYPLPKLDLVAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGF 316
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 419 ASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENF 498
Cdd:cd09601   317 ATYMEYLAVDKLFPEWNMWDQFVVDELQSALELDSLASSHPIEVPVESPSEISEIFDAISYSKGASVLRMLENFLGEEVF 396
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|....*.
gi 1829661130 499 QKGCQMYLEKYQFKNAKTSDFWAALEEAS----RLPVKEVMDTWTR 540
Cdd:cd09601   397 RKGLRKYLKKHAYGNATTDDLWEALQEASgeskPLDVKEIMDSWTL 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
92-584 4.34e-127

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 395.55  E-value: 4.34e-127
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130  92 RLPDFVNPVHYDLHVKPLLEEDTYTGTVSISIN-LSAPTRYLWLHLRETRITRLpelkrpSGDQVQVRrcFEYKKQEYVV 170
Cdd:COG0308    10 YRPPGYDVTHYDLDLDLDPATTRLSGTATITFTaTEAPLDSLVLDLKGLEVTSV------TVDGKPLD--FTRDGERLTI 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 171 VEAeeelTPSSGDGLYLLTMEFAGWLNGSLVGFYRTTYTENGqvKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHP 250
Cdd:COG0308    82 TLP----KPLAPGETFTLEIEYSGKPSNGGEGLYRSGDPPDG--PPYLYTQCEPEGARRWFPCFDHPDDKATFTLTVTVP 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 251 KEYGALSNMPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVF 330
Cdd:COG0308   156 AGWVAVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTFASGVPLRVYVRPGLADKAKEAFESTKRML 235
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 331 DYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYREtNLLYDpKESASSNQQRVATVVAHELVHQWFGNIVTMDWWE 410
Cdd:COG0308   236 DFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGE-KVLAD-ETATDADYERRESVIAHELAHQWFGNLVTCADWD 313
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 411 DLWLNEGFASFFEFLGVNHA--ETDWQMRDQMLLEDVLPVQedDSLMSSHPIIvtVTTPDEITSVFDGISYSKGSSILRM 488
Cdd:COG0308   314 DLWLNEGFATYMEQLFSEDLygKDAADRIFVGALRSYAFAE--DAGPNAHPIR--PDDYPEIENFFDGIVYEKGALVLHM 389
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 489 LEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTWTRQMGYPVLNVNGVKNiTQKRFLLDPRANP 568
Cdd:COG0308   390 LRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSAFFDQWLYQAGLPTLEVEYEYD-ADGKVTLTLRQTP 468
                         490
                  ....*....|....*.
gi 1829661130 569 SQPpsdlgYTWNIPVK 584
Cdd:COG0308   469 PRP-----HPFHIPLE 479
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
321-538 3.34e-112

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 342.35  E-value: 3.34e-112
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 321 YAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWF 400
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 401 GNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYS 480
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSEIDDIFDAIPYE 160
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*....
gi 1829661130 481 KGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEAS-RLPVKEVMDTW 538
Cdd:pfam01433 161 KGASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASgPLDVDSFMDTW 219
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
100-541 3.76e-99

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 316.38  E-value: 3.76e-99
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 100 VHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITR-------------------LPELKRPSGDQVQVRrc 160
Cdd:cd09602    16 VSYDLDLDLTEGAETFRGTVTIRFTLREPGASLFLDFRGGEVKSvtlngrpldpsafdgeritLPGLLKAGENTVVVE-- 93
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 161 FEYKKQeyvvveaeeeltpSSGDGLYlltmefagwlngslvgfyRTTYTENGQVksIVATDHEPTDARKSFPCFDEPNKK 240
Cdd:cd09602    94 FTAPYS-------------SDGEGLH------------------RFVDPADGET--YLYTLFEPDDARRVFPCFDQPDLK 140
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 241 ATYTISITHPKEYGALSNMPVAKEESVDDKwTRTTFEKSVPMSTYLVCFAVHQFDSVKRiSNSGKPLTIYVQPEQkhtAE 320
Cdd:cd09602   141 ATFTLTVTAPADWTVISNGPETSTEEAGGR-KRWRFAETPPLSTYLFAFVAGPYHRVED-EHDGIPLGLYCRESL---AE 215
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 321 YAAN------ITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYdpkESASSNQ-QRVATVVAH 393
Cdd:cd09602   216 YERDadeifeVTKQGLDFYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLFR---EEPTRAQrLRRANTILH 292
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 394 ELVHQWFGNIVTMDWWEDLWLNEGFASFFEFLGVNHA--ETD-WQmrdQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEI 470
Cdd:cd09602   293 EMAHMWFGDLVTMKWWDDLWLNESFADFMAAKALAEAtpFTDaWL---TFLLRRKPWAYRADQLPTTHPIAQDVPDLEAA 369
                         410       420       430       440       450       460       470
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 1829661130 471 TSVFDGISYSKGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTWTRQ 541
Cdd:cd09602   370 GSNFDGITYAKGASVLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRDLSAWADAWLRT 440
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
100-525 4.34e-94

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 302.06  E-value: 4.34e-94
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 100 VHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHlretriTRLPELKRPS--GDQVQvrrcfeYKKQEYVVVEAEEEL 177
Cdd:cd09595     1 YHYDLDLDVDFTTKTLNGTETLTVDASQVGRELVLD------LVGLTIHSVSvnGAAVD------FGEREHYDGEKLTIP 68
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 178 TPSSGDGLYLLTMEFAGWLNGSLVGFYRTTYTenGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPK-EYGAL 256
Cdd:cd09595    69 GPKPPGQTFTVRISFEAKPSKNLLGWLWEQTA--GKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKkDLLAS 146
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 257 SNMPVAKEE-SVDDKWTRttFEKSVPMSTYLVCFAVHQFDSVKR--ISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYF 333
Cdd:cd09595   147 NGALVGEETgANGRKTYR--FEDTPPIPTYLVAVVVGDLEFKYVtvKSQPRVGLSVYSEPLQVDQAQYAFDATRAALAWF 224
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 334 EEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSnqQRVATVVAHELVHQWFGNIVTMDWWEDLW 413
Cdd:cd09595   225 EDYFGGPYPLPKYDLLAVPDFNSGAMENPGLITFRTTYLLRSKVTDTGA--RSIENVIAHELAHQWFGNLVTMRWWNDLW 302
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 414 LNEGFASFFE--FLGVNHAETDWQMrDQMLLEDVLpvQEDDSLMSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLED 491
Cdd:cd09595   303 LNEGFAVYYEnrIMDATFGTSSRHL-DQLSGSSDL--NTEQLLEDSSPTSTPVRSPADPDVAYDGVTYAKGALVLRMLEE 379
                         410       420       430
                  ....*....|....*....|....*....|....
gi 1829661130 492 WIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEE 525
Cdd:cd09595   380 LVGEEAFDKGVQAYFNRHKFKNATTDDFIDALEE 413
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
101-538 2.81e-75

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 251.74  E-value: 2.81e-75
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 101 HYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRL------PELKRPSGDQVQVRRCFEYKKqeyvvveae 174
Cdd:cd09603     5 HYDLDLDYDPATKSLSGTATITFRATQDLDSLQLDLVGLTVSSVtvdgvpAAFFTHDGDKLVITLPRPLAA--------- 75
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 175 eeltpssgDGLYLLTMEFAGWLNGSLVGFYRTTYTENGqvKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYG 254
Cdd:cd09603    76 --------GETFTVTVRYSGKPRPAGYPPGDGGGWEEG--DDGVWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLT 145
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 255 ALSNMPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFE 334
Cdd:cd09603   146 VVSNGRLVSTTTNGGGTTTWHWKMDYPIATYLVTLAVGRYAVVEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFE 225
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 335 EYFAmNYSLPKLDKIAIPDFGtGAMENWGLITYRETNLLYDPKEsassnqqrvATVVAHELVHQWFGNIVTMDWWEDLWL 414
Cdd:cd09603   226 ELFG-PYPFEKYGQVVVPDLG-GGMEHQTATTYGNNFLNGDRGS---------ERLIAHELAHQWFGDSVTCADWADIWL 294
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 415 NEGFASFFEFLGVNHAETDWQMRDQMLledvlpvQEDDSLMSSHPIIVTVTTPDEItsvFDGISYSKGSSILRMLEDWIK 494
Cdd:cd09603   295 NEGFATYAEWLWSEHKGGADAYRAYLA-------GQRQDYLNADPGPGRPPDPDDL---FDRDVYQKGALVLHMLRNLLG 364
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|....
gi 1829661130 495 PENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTW 538
Cdd:cd09603   365 DEAFFAALRAYLARYAHGNVTTEDFIAAAEEVSGRDLTWFFDQW 408
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
202-548 3.02e-72

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 254.33  E-value: 3.02e-72
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 202 GFYRTTYTENGQVksIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSNmPVAKEESVDDKWTRTTFEKSVP 281
Cdd:TIGR02412 106 GLHRFVDPVDGEV--YLYTQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWTVISN-SRETDVTPEPADRRWEFPETPK 182
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 282 MSTYLVCFAVHQFDSVKRISNSgKPLTIYVQPE--QKHTAEYAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAM 359
Cdd:TIGR02412 183 LSTYLTAVAAGPYHSVQDESRS-YPLGIYARRSlaQYLDADAIFTITRQGLAFFHRKFGYPYPFKKYDQIFVPEFNAGAM 261
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 360 ENWGLITYREtNLLYDPKESASSNQQRVATVvAHELVHQWFGNIVTMDWWEDLWLNEGFASFFEFL------GVNHAETD 433
Cdd:TIGR02412 262 ENAGCVTFAE-NFLHRAEATRAEKENRAGVI-LHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLasaeatEYTDAWTT 339
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 434 W--QMRDQMLLEDVLPvqeddslmSSHPIIVTVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENFQKGCQMYLEKYQF 511
Cdd:TIGR02412 340 FaaQGKQWAYEADQLP--------TTHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEAFFAGVNAYFKRHAF 411
                         330       340       350
                  ....*....|....*....|....*....|....*..
gi 1829661130 512 KNAKTSDFWAALEEASRLPVKEVMDTWTRQMGYPVLN 548
Cdd:TIGR02412 412 GNATLDDLIDSLAKASGRDLSAWSDAWLETAGVNTLT 448
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
99-286 1.12e-65

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 217.60  E-value: 1.12e-65
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130  99 PVHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELT 178
Cdd:pfam17900   2 PEHYDLDLKIDLKNFTFSGSVTITLQLNNATNVIVLHASDLTIRSISLSDEVTSDGVPADFTEDQKDGEKLTIVLPETLN 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 179 PssgDGLYLLTMEFAGWLNGSLVGFYRTTYTENGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSN 258
Cdd:pfam17900  82 Q---TGPYTLEIEYSGELNDSMTGFYRSTYTDNGEKKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTALSN 158
                         170       180
                  ....*....|....*....|....*...
gi 1829661130 259 MPVAKEESVDDKWTRTTFEKSVPMSTYL 286
Cdd:pfam17900 159 MPVIASEPLENGWVITTFEQTPKMSTYL 186
ERAP1_C pfam11838
ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 ...
616-859 2.51e-63

ERAP1-like C-terminal domain; This large domain is composed of 16 alpha helices organized as 8 HEAT-like repeats. This domain forms a concave face that faces towards the active site of the peptidase.


Pssm-ID: 463368 [Multi-domain]  Cd Length: 316  Bit Score: 215.99  E-value: 2.51e-63
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 616 FLKINPDHIGFYRVNYEVATWDSIATALslNHKTFSSADRASLIDDAFALAR---------------------------- 667
Cdd:pfam11838   1 WVKLNADDTGYYRVNYDPESLAALLEQL--LSKVLSPLDRAGLIDDAFALARagelstsdaldlvlaylnetdyvvwsaa 78
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 668 ------------------------------------------------LLRSSVLGFACKMGDREALNNASSLFEQWLNG 699
Cdd:pfam11838  79 lsqlstlrsllsadpeyealkaflrkllsplaeklgweappgeshldrQLRALLLSAACSAGDPECVAEAKKLFDAWLDG 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 700 TVSLPVNLRLLVYRYGMQNsGNEISWNYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNLIKTQDVFTVI 779
Cdd:pfam11838 159 DDAIPPDLRWAVYCAAVAN-GGEAEWDALLERYRDTTSPSEKERALRALAATPDPELLQRALELALDSDEVRNQDLRAVI 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 780 RYISYNSYGKNMAWNWIQLNWDYLVNRYTLNNrNLGRIVT-IAEPFNTELQLWQMESFFAKYPQAGAgEKPREQVLETVK 858
Cdd:pfam11838 238 AGLASNPAGRDLAWDFVKENWDALVKRLGGGS-SLGRLVKgLTPSFSTEEELDEVEAFFADKDTPGL-RRALAQALETIR 315

                  .
gi 1829661130 859 N 859
Cdd:pfam11838 316 R 316
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
197-527 1.55e-34

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 137.65  E-value: 1.55e-34
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 197 NGSLVGFYRTtytengqvKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKE-YGA-LSNMPVAKEESVDDKWTRT 274
Cdd:cd09600    96 NTSLEGLYKS--------GGILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKEkYPVlLSNGNLIEEGELPNGRHFA 167
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 275 TFEKSVPMSTYLvcFAV--HQFDSVKR--ISNSGKP--LTIYVQPEQKHTAEYAANITKSVFDYFEEYFAMNYSLPKLDK 348
Cdd:cd09600   168 VWEDPFPKPSYL--FALvaGDLGSVEDtfTTKSGRKvkLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDLDLFNI 245
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 349 IAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWFGNIVTM-DWWEdLWLNEGFASFfeflgv 427
Cdd:cd09600   246 VAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCrDWFQ-LSLKEGLTVF------ 318
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 428 nhaetdwqmRDQMLLEDVL--PVQ--------------EDDSLMsSHPIivtvtTPD---EITSVFDGISYSKGSSILRM 488
Cdd:cd09600   319 ---------RDQEFSADMNsrAVKriedvrrlrsaqfpEDAGPM-AHPI-----RPDsyiEINNFYTVTVYEKGAEVIRM 383
                         330       340       350
                  ....*....|....*....|....*....|....*....
gi 1829661130 489 LEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEAS 527
Cdd:cd09600   384 LHTLLGEEGFRKGMDLYFERHDGQAVTCEDFVAAMEDAS 422
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
241-538 1.08e-31

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 129.32  E-value: 1.08e-31
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 241 ATYTISITHPKEY-----GALSNmpvakEESVDDKWTRTTFE-KSVPMstylVCFAVHQFDSVKRISNSGKPLTIYVQPE 314
Cdd:cd09604   161 GDYDVTITVPKNYvvaatGELQN-----PEEVLDGTKTWHFKaENVRD----FAWAASPDFVVDAATVDGVTVNVYYLPE 231
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 315 QKHTAEYAANITKSVFDYFEEYFaMNYSLPKLDkIAIPDFGTGAMENWGLITYRETnlLYDPKESassnqqrVATVVAHE 394
Cdd:cd09604   232 NAEAAERALEYAKDALEFFSEKF-GPYPYPELD-VVQGPFGGGGMEYPGLVFIGSR--LYDPKRS-------LEGVVVHE 300
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 395 LVHQWFGNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLmsshPIIVTVTTPDEITSVF 474
Cdd:cd09604   301 IAHQWFYGIVGNDERREPWLDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYARGPGG----PINLPLDTFPDGSYYS 376
                         250       260       270       280       290       300
                  ....*....|....*....|....*....|....*....|....*....|....*....|....
gi 1829661130 475 DgISYSKGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTW 538
Cdd:cd09604   377 N-AVYSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAEEVSGKDLDWFFRGW 439
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
223-525 2.60e-31

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 127.96  E-value: 2.60e-31
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 223 EPTDARKSFPCFDEPNKKATYTISITHPKEYGAL-SNMPVakEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSvKRIS 301
Cdd:cd09599   132 QAIHARSLFPCQDTPSVKSTYSATVTVPKGLTALmSALRT--GEKEEAGTGTYTFEQPVPIPSYLIAIAVGDLES-REIG 208
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 302 N-SGkpltIYVQPEQ-KHTAEYAANITKSVfDYFEEYFaMNYS--------LPkldkiaiPDFGTGAMENwGLITYretn 371
Cdd:cd09599   209 PrSG----VWAEPSVvDAAAEEFADTEKFL-KAAEKLY-GPYVwgrydllvLP-------PSFPYGGMEN-PCLTF---- 270
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 372 llydpkesAS--------SNqqrvATVVAHELVHQWFGNIVTMDWWEDLWLNEGFASFFE------FLGVNHAETDWQMR 437
Cdd:cd09599   271 --------ATptliagdrSL----VDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYLErrilerLYGEEYRQFEAILG 338
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 438 DQMLLEDVLPVQEDDSLMSSHPIIVTVtTPDEitsVFDGISYSKGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTS 517
Cdd:cd09599   339 WKDLQESIKEFGEDPPYTLLVPDLKGV-DPDD---AFSSVPYEKGFQFLYYLEQLGGREVFDPFLRAYFKKFAFQSIDTE 414

                  ....*...
gi 1829661130 518 DFWAALEE 525
Cdd:cd09599   415 DFKDFLLE 422
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
94-525 8.02e-29

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 122.58  E-value: 8.02e-29
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130  94 PDFVNPVHYDLHVKPLLEEDTYTGTVSISIN-LSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRcfEYKKQEYVVVE 172
Cdd:TIGR02411   8 YKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKsLTDNLNKLVLDTSYLDIQKVTINGLPADFAIGERK--EPLGSPLTISL 85
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 173 AEEeltPSSGDGLyLLTMEFAGWLNGSLVGFYRTTYTEnGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPke 252
Cdd:TIGR02411  86 PIA---TSKNDEF-VLNISFSTTPKCTALQWLNPEQTS-GKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVESP-- 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 253 YGAL-SNMPvaKEESVDDKwTRTTFEKSVPMSTYLVCFAVHQFDSvkriSNSGKPLTIYVQPEQKHTAEYAANITKSVFD 331
Cdd:TIGR02411 159 LPVLmSGIR--DGETSNDP-GKYLFKQKVPIPAYLIAIASGDLAS----APIGPRSTVYSEPEQLEKCQYEFENDTEKFI 231
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 332 YFEEYFAMNYSLPKLDKIAIPD-FGTGAMENwGLITYRETNLLydpkesasSNQQRVATVVAHELVHQWFGNIVTMDWWE 410
Cdd:TIGR02411 232 KTAEDLIFPYEWGQYDLLVLPPsFPYGGMEN-PNLTFATPTLI--------AGDRSNVDVIAHELAHSWSGNLVTNCSWE 302
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 411 DLWLNEGFASFFE--FLGVNHAEtdwQMRDQMLLEDVLPVQEDDSLMSSHP----IIVTVTT--PDEitsVFDGISYSKG 482
Cdd:TIGR02411 303 HFWLNEGWTVYLErrIIGRLYGE---KTRHFSALIGWGDLQESVKTLGETPeftkLVVDLKDndPDD---AFSSVPYEKG 376
                         410       420       430       440
                  ....*....|....*....|....*....|....*....|....
gi 1829661130 483 SSILRMLEDWI-KPENFQKGCQMYLEKYQFKNAKTSDFWAALEE 525
Cdd:TIGR02411 377 FNFLFYLEQLLgGPAEFDPFLRHYFKKFAYKSLDTYQFKDALYE 420
pepN PRK14015
aminopeptidase N; Provisional
303-562 2.76e-17

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 87.11  E-value: 2.76e-17
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 303 SGK--PLTIYVQPEQKHTAEYA-ANITKSV-FDyfEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLityretNL------ 372
Cdd:PRK14015  210 SGRevALEIYVEPGNLDKCDHAmDSLKKSMkWD--EERFGLEYDLDIFMIVAVDDFNMGAMENKGL------NIfnskyv 281
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 373 LYDPkESAS-SNQQRVATVVAHELVHQWFGNIVTM-DWWEdLWLNEGFASFfeflgvnhaetdwqmRDQMLLEDVL--PV 448
Cdd:PRK14015  282 LADP-ETATdADYERIESVIAHEYFHNWTGNRVTCrDWFQ-LSLKEGLTVF---------------RDQEFSADLGsrAV 344
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 449 Q--------------EDDSLMSsHPIivtvtTPD---EI-----TSVfdgisYSKGSSILRMLEDWIKPENFQKGCQMYL 506
Cdd:PRK14015  345 KriedvrvlraaqfaEDAGPMA-HPV-----RPDsyiEInnfytATV-----YEKGAEVIRMLHTLLGEEGFRKGMDLYF 413
                         250       260       270       280       290
                  ....*....|....*....|....*....|....*....|....*....|....*.
gi 1829661130 507 EKYQFKNAKTSDFWAALEEASRLPVKEVMdTWTRQMGYPVLNVNGVKNITQKRFLL 562
Cdd:PRK14015  414 ERHDGQAVTCEDFVAAMEDASGRDLSQFR-RWYSQAGTPRVTVSDEYDAAAGTYTL 468
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
231-421 7.23e-11

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 65.71  E-value: 7.23e-11
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 231 FPCFDEPNKKATYTISITHPKEYGALSNMPVAKEESVDDKW-----------------------------TRTT--FEKS 279
Cdd:cd09839   180 FPCVDSLWERCTWELEITVPRTLGDAGRPPLAGSKEDEDDDdlteedkelemvvvcsgdlveqvvhpedpSKKTfsFSLS 259
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 280 VPMSTYLVCFAVHQFDSVK-----------RISNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFAM----NYSLP 344
Cdd:cd09839   260 NPTSAQHIGFAVGPFEIVPlpefreseeddKLGSSAVEVTGFCLPGRLEELRNTCSFLHKAMDFFEEEYGSypfsSYKQV 339
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 1829661130 345 KLDKiAIPDFGTGAmenwGLITYrETNLLYDPK--ESASSNQQrvatVVAHELVHQWFGNIVTMDWWEDLWLNEGFASF 421
Cdd:cd09839   340 FVDD-LPEDVSSFA----SLSIC-SSRLLYPPDiiDQAYETRR----KLAHALASQWFGINIIPKTWSDTWLVIGIAGY 408
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
325-425 8.10e-10

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 56.72  E-value: 8.10e-10
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1829661130 325 ITKSVFDYFEEYF----AMNYSLPKLDKIAIPDFGTGAMENwGLITYrETNLLYDPKESASSNQQRVatVVAHELVHQWF 400
Cdd:cd09594     3 YAHETYKYYEELLgrtsFRYPVSPIYSLLVYPAYVEVNAYN-AMWIP-STNIFYGAGILDTLSGTID--VLAHELTHAFT 78
                          90       100
                  ....*....|....*....|....*.
gi 1829661130 401 GNIVTMDW-WEDLWLNEGFASFFEFL 425
Cdd:cd09594    79 GQFSNLMYsWSSGWLNEGISDYFGGL 104
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH